NCT03663686View on ClinicalTrials.gov

The Safety, Tolerability and Pharmacokinetic Study of Litapiprant Tablets in Healthy Male and Female Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

October 25, 2018

Primary Completion Date

January 30, 2019

Study Completion Date

January 30, 2019

Conditions
Asthma
Interventions
DRUG

Litapiprant Tablet

Small molecules inhibitors of the chemoattractant receptor homologous molecule expressed on Th2 cells

Trial Locations (1)

100038

Beijing shijitan hospital, Beijing

All Listed Sponsors
lead

Sunshine Lake Pharma Co., Ltd.

INDUSTRY

NCT03663686 - The Safety, Tolerability and Pharmacokinetic Study of Litapiprant Tablets in Healthy Male and Female Subjects | Biotech Hunter | Biotech Hunter